

Applicant: D. Berd  
Serial No.: 09/036,645

had a right to claim. Applicants incorporate by Reference the Amendment filed with the Reissue Request on March 6, 1998. The amendments do not add new matter. Consideration and allowance is respectfully requested.

Also submitted is a Statement Under 37 C.F.R. §3.73(b) confirming the authority of the assignee, Thomas Jefferson University, assenting to this reissue.

**IN THE CLAIMS:**

(All claims that have been indicated as allowable are reproduced for the Examiner's convenience. Claims 1 and 2, which have not been amended, are indicated as "Unchanged.")

1. (Unchanged) A vaccine useful for the treatment of melanoma comprising irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-5 sulfonic 1-naphtyl ethylene diamine; and mixed with an immunological adjuvant, wherein said immunological adjuvant is *Bacille Calmette-Guerin*.

2. (Unchanged) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of the vaccine of claim 1.

Please cancel informal claims 3, 5, 7-9, 13, 15-17, and 19 without prejudice.

Applicant: D. Berd  
Serial No.: 09/036,645

Please add the following new claims:

3.  
~~21~~ The vaccine of claim 1, wherein said autologous melanoma cells are cryopreserved.

4.  
~~22~~ The method of claim 2, wherein said autologous melanoma cells are cryopreserved.

5.  
~~23~~ The method of claim 2, wherein said vaccine is injected into three contiguous sites on an upper arm or leg.

6.  
~~24~~ The method of claim 2, wherein said vaccine is administered to post-surgical melanoma patients.

7.  
~~25~~ The method of claim 2, wherein said vaccine is administered to stage four melanoma patients.

8.  
~~26~~ A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of a vaccine composition comprising cryopreserved and irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl,